President Donald Trump is set to fire FDA Commissioner Marty Makary, The Wall Street Journal reports, citing sources familiar ...

With an FDA decision date looming for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Capricor Therapeutics has filed a ...

With its largest-ever acquisition, Angelini gains 24-year-old Catalyst, which was listed on the Nasdaq in 2006. Catalyst ...

After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the ...

Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a 95 billion ...

Summit Therapeutics' closely watched PD-1xVEGF study surprisingly missed its mark at an interim analysis. | Summit's ...

GSK is teaming up with “Modern Family” stars Julie Bowen and Ty Burrell to help get out the messaging: “ask to be sure” about ...

Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a ...

In the latest update to COVID and vaccine-related discourse bubbling up at the FDA, agency officials have recently blocked ...

Novartis is continuing its multiyear overhaul with new plans to shutter its production facility in Wehr, Germany. | Novartis ...

Since the start of the decade, Eli Lilly has committed to spend more than $50 billion to bolster its United States ...

After a surprise rejection at the beginning of 2026, the FDA has agreed to reconsider a T-cell therapy based on the same ...